Blog

On Saturday, May 16, approximately 110 people, including neuroendocrine cancer patients, caregivers, clinicians, scientists, advocates, and industry partners, gathered in Atlanta, Georgia, for the Neuroendocrine Cancer Foundation Patient Education Event. Designed specifically for individuals living with neuroendocrine cancer (or NET) and their loved ones, this full-day program brought together leading regional experts from Emory University, the University of Alabama at Birmin

Recapping the SNMMI Neuroendocrine Cancer Patient Education Event On May 31st, the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Neuroendocrine Cancer Patient Education Day brought the NET community to the Los Angeles Convention Center, co-organized by the Neuroendocrine Cancer Foundation (NCF) and NorCal CarciNET's Josh Mailman alongside the SNMMI Annual Conference. Offered completely free and in a hybrid format, the event opened doors for patients and famil

We thank Jaydira Del Rivero, MD, for reviewing this blog post. In March 2025, the U.S. FDA approved a new treatment option for neuroendocrine tumors: cabozantinib. (Cabometyx® is the brand name of this medication, manufactured by Exelixis.) Although this pill has long been used to treat other cancers, it is now approved for patients 12 years and older with previously treated, advanced neuroendocrine tumors. 👉 For background on the CABINET trial and what the trial data showed